[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","e11x3cwp7p5295xwgr41f9eis","revision",2,"title","Vivos Therapeutics 符合纳斯达克上市要求","originalTitle","8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)","summary","Vivos Therapeutics 通过纳斯达克最低股东权益要求。公司称其符合纳斯达克上市规则 5550(b)(1) 要求。若下次财报无法证明合规，可能面临退市风险。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-21T11:00:14.000Z","discoveredAt","2026-10-21T11:05:37.950Z","timelineAt","category","tip","tags",[80,81,82],"stockSymbols",[79],"score",37,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fXAX2cUFWbzk",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","2ac67e72-c077-48ad-b69b-a3b51b91a8bd",{"_72":73,"_15":16},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

FORM\n8-K

CURRENT\nREPORT

Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934

Date\nof Report (Date of earliest event reported): October 20, 2026

VIVOS\nTHERAPEUTICS, INC.

(Exact\nname of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware

001-39796

81-3224056

(State\n or other jurisdiction

of\n incorporation)

(Commission

File\n Number)

(IRS\n Employer

Identification\n No.)

7921\nSouthpark Plaza, Suite 210, Littleton, Colorado 80120

(Address\nof principal executive offices) (Zip Code)

Registrant’s\ntelephone number, including area code: (866) 908-4867

Not\nApplicable

(Former\nname or former address, if changed since last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:

\n\n \n \n

☐	Written communications pursuant\n to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n \n \n

☐	Soliciting material pursuant\n to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n \n \n

☐	Pre-commencement communications\n pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n \n \n

☐	Pre-commencement communications\n pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading\n Symbol(s)		Name\n of each exchange on which registered
Common\n Stock, $0.0001 par value per share		VVOS		The\n Nasdaq Stock Market LLC

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging\ngrowth company ☐

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item\n8.01 Other Events.

As\npreviously disclosed, in April 2026 Vivos Therapeutics, Inc. (the “Company”) received a deficiency notice from the Listing\nQualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not\ncomply with the continued listing requirements of Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require a listed\ncompany to maintain a minimum of $2.5 million in stockholders’ equity, a minimum $35 million market value of listed securities,\nor a minimum of $500,000 of net income from continuing operations, respectively.

On\nOctober 20, 2026, the Company received a letter from the Staff stating that, based on the Company’s Current Report on Form 8-K\nfiled October 19, 2026, the Staff has determined that the Company complies with the minimum stockholders’ equity requirement of\nNasdaq Listing Rule 5550(b)(1). The letter further stated that if the Company fails to evidence compliance upon the filing of its next\nperiodic report, the Company may be subject to delisting, in which case the Staff would provide written notification to the Company,\nwhich may then appeal the Staff’s determination to a Nasdaq Hearings Panel.

Forward-Looking\nStatements

This\nCurrent Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of\n1995, including statements regarding the Company’s continued compliance with Nasdaq’s continued listing requirements. Forward-looking\nstatements are subject to risks and uncertainties that could cause actual results to differ materially, including: (i) the risk that\nthe Company does not evidence compliance with the minimum stockholders’ equity requirement upon the filing of its next periodic\nreport; (ii) the risk that the Company’s independent registered public accounting firm or Nasdaq reaches conclusions regarding\nthe Company’s accounting treatment or stockholders’ equity that differ from the Company’s expectations; and (iii) the\nother risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report\non Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this Current Report on Form\n8-K, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information,\nfuture events or otherwise, except as required by law.

Item\n9.01 Financial Statements and Exhibits.

(d)\nExhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description
99.1		Press Release of Vivos Therapeutics, Inc. dated October 21, 2026 (furnished, not filed)
104		Cover\n Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	VIVOS THERAPEUTICS, INC.

Date:\n October 21, 2026	By:	/s/\n Roman Franklin
	Name:	Roman Franklin
	Title:	Chief Financial Officer

","zhKind","complete","VVOS","政策与监管","退市","Nasdaq","aihot","/items/e11x3cwp7p5295xwgr41f9eis","https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/0001493152-26-047841-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792800000&sig=a1281a539589308a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792800000&sig=57a86ea6a382db0f 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792800000&sig=f9807010575fb678 96w","changelogVersion","2026-10-01T08:00"]